Protalix BioTherapeutics Inc (PLX)

Add to Watchlists

Create an Alert

Quickflows

3.59 -0.03 -0.83% NYSE AM Aug 7, 20:00 USD

Protalix BioTherapeutics News

Wire

Headline

Time (ET)
PR Newswire

Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020

08/06 13:02
PR Newswire

Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020

08/03 09:13
PR Newswire

Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases

07/23 14:29
Yahoo

Edited Transcript of PLX.A earnings conference call or presentation 1-Jun-20 12:30pm GMT

07/22 19:28
Yahoo

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?

06/18 12:20
PR Newswire

Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development

06/08 17:00
MT Newswires

--Analyst Actions: HC Wainwright Lifts Price Target on Protalix BioTherapeutics to $11 From $3, Reiterates Buy Rating

06/08 10:00
Yahoo

Edited Transcript of PLX earnings conference call or presentation 12-Mar-20 12:30pm GMT

06/03 20:46
SA Breaking News

Protalix Bio +3% on Q1 results

06/01 07:32
MT Newswires

-- Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS INC. Posts Q1 Revenue $21.646M

06/01 07:07
SA Breaking News

Protalix BioTherapeutics EPS beats by $0.40

06/01 06:55
PR Newswire

Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update

06/01 06:50
Yahoo

Protalix Biotherapeutics, Inc. to Host Earnings Call

06/01 06:30
Yahoo

Protalix Submits BLA for Fabry Disease Candidate PRX-102

05/29 09:43
MT Newswires

Israel's Protalix BioTherapeutics Submits License Application to FDA for PRX-102 to Treat Fabry Disease; Stock Up Near 6%

05/28 13:03
SA Breaking News

U.S. application filed for Protalix Bio's pegunigalsidase alfa for Fabry

05/28 07:51
PR Newswire

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

05/28 06:50
PR Newswire

Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020

05/22 16:05
MT Newswires

Sector Update: Large Rise for Health Care Stocks Keeping Nasdaq Composite, S&P 500 on Positive Ground

05/11 15:53
MT Newswires

Protalix BioTherapeutics Jumps as Fabry Disease Phase 3 Trial Delivers 'Positive' Topline Results

05/11 14:58

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial

{{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.